Peptides in the treatment of AIDS.
Fusion of HIV-1 and target cells is mediated by the envelope protein gp41 that undergoes a series of conformational changes during the process of infection. Knowledge of the structural biology of gp41 allows the design of potent peptide inhibitors that prevent the virus from entering lymphocytes and macrophages. The design of such inhibitors is the subject of this review.
Naider
Fred
F
Department of Chemistry, College of Staten Island of the City University of New York, Staten Island, New York 10314, USA. naider@mail.csi.cuny.edu
Anglister
Jacob
J
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D000595:Amino Acid Sequence; D000818:Animals; D015195:Drug Design; D023581:HIV Fusion Inhibitors / Q000737:chemistry* / Q000494:pharmacology* / Q000627:therapeutic use; D015497:HIV-1 / Q000187:drug effects / Q000378:metabolism / Q000502:physiology; D006801:Humans; D008969:Molecular Sequence Data; D010455:Peptides / Q000737:chemistry* / Q000494:pharmacology* / Q000627:therapeutic use; D014759:Viral Envelope Proteins / Q000737:chemistry / Q000378:metabolism
D023581:HIV Fusion Inhibitors; D010455:Peptides; D014759:Viral Envelope Proteins